Alectinib-Induced Erythema Multiforme and Successful Rechallenge with Alectinib in a Patient with Anaplastic Lymphoma Kinase-Rearranged Lung Cancer

BACKGROUND: Alectinib is an oral drug developed for the treatment of patients with fusion gene encoding echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK)-rearranged non-small cell lung cancer (NSCLC). Here, we present the case of a patient treated with alectinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimura, Tatsuo, Sowa-Osako, Junko, Nakai, Toshiyuki, Ohyama, Ayako, Kawaguchi, Tomoya, Tsuruta, Daisuke, Ohsawa, Masahiko, Hirata, Kazuto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216233/
https://www.ncbi.nlm.nih.gov/pubmed/28101031
http://dx.doi.org/10.1159/000453314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216233/
https://www.ncbi.nlm.nih.gov/pubmed/28101031
http://dx.doi.org/10.1159/000453314

Ejemplares similares